Last reviewed · How we verify

NCT05154448

Double Arm Pivotal Study to Evaluate the Neurolyser XR for the Treatment of Chronic Low Back Pain

Completed NA Last updated 7 February 2025
What this trial tests

NA trial testing Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR) in Facet Syndrome of Lumbar Spine in 90 participants. Completed in 16 April 2024.

Timeline
16 May 2022
Primary endpoint
16 April 2024
16 April 2024

Quick facts

Lead sponsorFUSMobile Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment90
Start date16 May 2022
Primary completion16 April 2024
Estimated completion16 April 2024
Sites10 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

FUSMobile Inc.

Who can join

Adults 50 to 85, any sex, with Facet Syndrome of Lumbar Spine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Double arm pivotal study to evaluate the Neurolyser XR as a non-invasive treatment of axial chronic low back pain

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Facet Syndrome of Lumbar Spine

Currently open trials in the same condition.

Other FUSMobile Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05154448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing